The efficacy and safety of silodosin for the treatment of ureteral stones: a systematic review and meta-analysis

BMC Urology

Table 1 Study and patient characteristics

Study	Therapy in experimental group	Therapy in control group	Country	Sample size		Administration method	Duration of treatment	Dosage	Stone location and size range
Study	Therapy in experimental group	Therapy in control group	Country	experimental	Control	Administration method	Duration of treatment	Dosage	Stone location and size range
Itoh Y 2011	silodosin	blank control	Japan	95	92	Oral	8 wk	8mg/d	symptomatic unilateral ureteral calculi of less than 10 mm
Tsuzaka Y 2011	silodosin	naftopidil	Japan	35	39	Oral	6 wk	8mg/d	symptomatic≤10 mm ureteral stones
Guptas S 2013	silodosin	tamsulosin	India	50	50	Oral	4 wk	8mg/d	unilateral, uncomplicated middle or lower ureteral stones ≤10 mm
Dell'Atti L 2014	silodosin	tamsulosin	Italy	68	68	Oral	3 wk	8mg/d	single, unilateral, radiopaque, proximal ureteral stone (range 4–10 mm in size)
Sur RL 2014	silodosin	placebo	USA	119	120	Oral	4 wk	8mg/d	unilateral ureteral calculus of 4–10 mm
Kumar S 2015	silodosin	tamsulosin	India	90	90	Oral	4 wk	8mg/d	distal ureteric stones of size 5–10 mm

ISSN: 1471-2490